The finding will likely help physicians develop targeted therapies for future COVID patients.

Researchers say the support program could be extended to many patient populations.

The findings are a promising step for a disease with limited treatment options.

Study in people taking a biologic drug for autoimmune diseases shows association of patient support programs with reduced chance of starting opioid pain medicines or continuing on them.

A new potential biomarker raises concerns over the current standard for treating COVID-19 induced blood clots with high dose blood thinners.

Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.